Pfizer breaks ground on new R&D facility in Chesterfield, Missouri
- Details
- Category: Pfizer
Pfizer Inc., (NYSE:PFE) one of the world's premier biopharmaceutical companies, broke ground on a state-of-the art Research and Development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield, MO. The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations which the company leases in the St. Louis area.
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL).
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
- Details
- Category: Novartis
Novartis today announced topline results from the global Phase III CANTOS study investigating the efficacy, safety and tolerability of ACZ885 (canakinumab) in combination with standard of care in people with a prior heart attack and inflammatory atherosclerosis. With more than 10,000 patients enrolled in the study over the last six years, CANTOS is one of the largest and longest-running clinical trials in Novartis' history.
Merck Foundation established
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced the establishment of the Merck Foundation. Through this foundation Merck combines many of its corporate responsibility activities under one roof and considerably expands its scope to address health, social and economic challenges of the 21st century.
The made-in-Italy fast-track acceleration program dedicated to projects in life science
- Details
- Category: Business
ZCube, Research Venture of the pharmaceutical group Zambon, announced the second edition of Open Accelerator, the made-in-Italy fast track acceleration program dedicated to projects in life science fields. Open Accelerator is a 12-steps program providing training to international researchers, scientists and aspiring entrepreneurs that following a selection could receive a seed investment of up to a maximum of 100.000 EUR for each project.
Merck Ventures creates new immuno-oncology company iOnctura
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology (CRT).
New patient survey highlights need for more action to help severe asthma patients gain control of their disease
- Details
- Category: Novartis
Novartis announced the results of a new survey of 904 severe asthma patients, presented for the first time at the European Academy of Allergy and Clinical Immunology (EAACI) Congress[1]. Data from the 'Still Fighting for Breath' survey demonstrate that, despite the widespread availability of oral and inhaled treatments, asthma still places a huge burden on the personal and professional lives of those living with the disease in Europe.
More Pharma News ...
- Bristol-Myers Squibb to sell manufacturing facility in Swords, Ireland to SK Biotek Co., Ltd.
- Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®
- Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial
- Roche's employee-driven philanthropic campaign sets new record
- Pfizer and Lilly receive FDA Fast Track designation for tanezumab
- Bayer Grants4Apps® Dealmaker Berlin 2017
- Boehringer Ingelheim builds Digital Lab "BI X" with focus on innovative digital solutions in healthcare